Lysophosphatidic acid acyltransferase-β: A novel target for induction of tumour cell apoptosis

Expert Opinion on Therapeutic Targets

Volumn 7, Issue 5, 2003, Pages 643-661

  Bonham, Lynn ^a   Leung, David W ^a   White, Thayer ^a   Hollenback, David ^a   Klein, Peter ^a   Tulinsky, John ^a   Coon, Michael ^a   de Vries, Peter ^a   Singer, Jack W ^a  

^a Cell Therapeutics Inc   (United States)

Author keywords

Akt; Apoptosis; Erk; Lysophosphatidic acid acyltransferase (LPAAT); Mammalian target of rapamycin (mTor); Oncogenesis; Phosphatidic acid (PA); Raf

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ACYLTRANSFERASE; ACYLTRANSFERASE INHIBITOR; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; COMPLEMENTARY DNA; CT 32169; CT 32176; CT 32212; CT 32228; CT 32405; CT 32424; CT 32458; CT 32494; CT 32495; CT 32520; CT 32525; GELDANAMYCIN; IMATINIB; ISOENZYME; LYSOPHOSPHATIDIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDIC ACID; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAPAMYCIN; RAS PROTEIN; RETINOIC ACID; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW; CARCINOGENESIS; CATALYSIS; CELL ACTIVITY; CELL MEMBRANE; CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; IC 50; IN VITRO STUDY; LIPOGENESIS; LUNG TUMOR; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STEM CELL; STRUCTURE ANALYSIS; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM;

EID: 0141961580     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.7.5.643     Document Type: Review

References (75)

1. GHOSH S, STRUM JC, SCIORRA VA, DANIEL L, BELL RM: Raf-1 kinase possesses distinct binding domains for phosphatidylserine and phosphatidic acid. Phosphatidic acid regulates the translocation of Raf-1 in 12-O-tetradecanoylphorbol-13-acetate-stimulated Madin-Darby canine kidney cells. J. Biol. Chem. (1996) 271:8472-8480.
2. RIZZO MA, SHOME K, WATKINS SC, ROMERO G: The recruitment of Raf-1 to membranes is mediated by direct interaction with phosphatidic acid and is independent of association with Ras. J. Biol. Chem. (2000) 275:23911-23918.
3. FANG Y, VILELLA-BACH M, BACHMANN R, FLANIGAN A, CHEN J: Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science (2001) 294:1942-1945.
4. CAPDEVILLE R, BUCHDUNGER E, ZIMMERMANN J, MATTER A: Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. (2002) 1:493-502.
5. SCHINDLER T, BORNMANN W, PELLICENA P et al.: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 289:1938-1942.
6. HEINRICH MC, CORLESS CL, DUENSING A et al.: PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 299:708-710.
7. APPERLEY JF, GARDEMBAS M, MELO JV et al.: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor β. N. Engl. J. Med. (2002) 347:481-487.
8. ZHU J, LALLEMAND-BREITENBACH V, DE THE H: Pathways of retinoic acid- or arsenic trioxide-induced PML/RARα catabolism, role of oncogene degradation in disease remission. Oncogene (2001) 20:7257-7265.
9. ZHANG TD, CHEN GQ, WANG ZG et al.: Arsenic trioxide, a therapeutic agent for APL. Oncogene (2001) 20:7146-7153.
10. MILLER WH Jr, SCHIPPER HM, LEE JS, SINGER J, WAXMAN S: Mechanisms of action of arsenic trioxide. Cancer Res. (2002) 62:3893-3903.
11. ZHU J, CHEN Z, LALLEMAND-BREITENBACH V, DE THE H: How acute promyelocytic leukaemia revived arsenic. Nat. Rev. Cancer (2002) 2:705-713.
12. KELLY LM, YU JC, BOULTON CL et al.: CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell (2002) 1:421-432.
13. WEISBERG E, BOULTON C, KELLY LM et al.: Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell (2002) 1:433-443.
14. TAVERAS AG, REMISZEWSKI SW, DOLL RJ et al.: Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex. Bioorg. Med. Chem. (1997) 5:125-133.
15. WORKMAN P: New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges. Curr. Cancer Drug Targets (2001) 1:33-47.
16. KERBEL R, FOLKMAN J: Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer (2002) 2:727-739.
17. MAKI RG, AWAN RA, DIXON RH, JHANWAR S, ANTONESCU CR: Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int. J. Cancer (2002) 100:623-626.
18. RUBIN BP, SCHUETZE SM, EARY JF et al.: Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol. (2002) 20:3586-3591.
19. JOHNSTONE RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. (2002) 1:287-299.
20. ADAMS J: Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr. Opin. Chem. Biol. (2002) 6:493-500.
21. DEVERAUX QL, SCHENDEL SL, REED JC: Antiapoptotic proteins. The bcl-2 and inhibitor of apoptosis protein families. Cardiol. Clin. (2001) 19:57-74.
22. MURAKAMI MS, MORRISON DK: Raf-1 without MEK? Sci. STKE (2001) 2001:E30.
23. STEBBINS CE, RUSSO AA, SCHNEIDER C et al.: Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell (1997) 89:239-250.
24. HOOD JD, BEDNARSKI M, FRAUSTO R et al.: Tumor regression by targeted gene delivery to the neovasculature. Science (2002) 296:2404-2407.
25. HALUSKA P, DY G, ADJEI A: Farnesyl transferase inhibitors as anticancer agents. Eur. J. Cancer (2002) 38:1685-1700.
26. MCPHAIL LC, WAITE KA, REGIER DS et al.: A novel protein kinase target for the lipid second messenger phosphatidic acid. Biochm. Biophys. Acta (1999) 1439:277-290.
27. ATHENSTAEDT K, DAUM G: Phosphatidic acid, a key intermediate in lipid metabolism. Eur. J. Biochem. (1999) 266:1-16.
28. HODGKIN MN, PETTITT TR, MARTIN A et al.: Diacylglycerols and phosphatidates: which molecular species are intracellular messengers? Trends Biochem. Sci. (1998) 23:200-204.
29. JOSEPH T, WOODEN R, BRYANT A et al.: Transformation of cells overexpressing a tyrosine kinase by phospholipase D1 and D2. Biochem. Biophys. Res. Commun. (2001) 289:1019-1024.
30. KANOH H, YAMADA K, SAKANE F: Diacylglycerol kinases: emerging downstream regulators in cell signaling systems. J. Biochem. (Tokyo) (2002) 131:629-633.
31. EBERHARDT C, GRAY PW, TJOELKER LW. Human lysophosphatidic acid acyltransferase. cDNA cloning, expression, and localization to chromosome 9q34.3. J. Biol Chem. (1997) 272:20299-20305.
32. AGUADO B, CAMPBELL RD: Characterization of a human lysophosphatidic acid acyltransferase that is encoded by a gene located in the Class III region of the human major histocompatibility complex. J. Biol. Chem. (1998) 273:4096-4105.
33. LEUNG DW: The structure and functions of human lysophosphatidic acid acyltransferases. Front. Biosci. (2001) 6:D944-D953.
34. AGARWAL AK, ARIOGLU E, DE ALMEIDA S et al.: AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat. Genet. (2002) 31:21-23.
35. ALTSCHUL SF, MADDEN TL, SCHAFFER AA et al.: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. (1997) 25:3389-3402.
36. NAGIEC MM, WELLS GB, LESTER RL, DICKSON RC: A suppressor gene that enables Saccharomyces cerevisiae to grow without making sphingolipids encodes a protein that resembles an Escherichia coli fatty acyltransferase. J. Biol. Chem. (1993) 268:22156-22163.
37. KNUTZON DS, LARDIZABAL KD, NELSEN JS et al.: Cloning of a coconut endosperm cDNA encoding a 1-acyl-sn-glycerol-3-phosphate acyltransferase that accepts medium-chain-length substrates. Plant Physiol. (1995) 109:999-1006.
38. WEST J, TOMPKINS C, BALANTAC N et al.: Cloning and expression of two human lysophosphatidic acid acyltransferase cDNAs that stimulate cytokine induced signaling responses in cells. DNA Cell Biol. (1997) 16:691-701.
39. CSERZO M, WALLIN E, SIMON I, VON HEIJNE G, ELOFSSON A: Prediction of transmembrane α-helices in prokaryotic membrane proteins: the dense alignment surface method. Protein Eng. (1997) 10:673-676.
40. DIRKS WG, MACLEOD RA, DREXLER HG: ECV304 (endothelial) is really T24 (bladder carcinoma): cell line cross-contamination at source. In Vitro Cell. Dev. Biol. Anim. (1999) 35:558-559.
41. SCHMIDT A, WOLDE M, THIELE C et al.: Endophilin I mediates synaptic vesicle formation by transfer of arachidonate to lysophosphatidic acid. Nature (1999) 401:133-141.
42. WEIGERT R, SILLETTA MG, SPANO S et al.: CtBP/BARS induces fission of Golgi membranes by acylating lysophosphatidic acid. Nature (1999) 402:429-433.
43. BARR FA, SHORTER J: Membrane traffic: do cones mark sites of fission? Curr. Biol. (2000) 10:R141-R144.
44. LEWIN TM, WANG P, COLEMAN RA: Analysis of amino acid motifs diagnostic for the sn-glycerol-3-phosphate acyltransferase reaction. Biochemistry (Mosc.) (1999) 38:5764-5771.
45. HEATH RJ, ROCK CO: A conserved histidine is essential for glycerolipid acyltransferase catalysis. J. Bacteriol. (1998) 180:1425-1430.
46. TURNBULL AP, RAFFERTY JB, SEDELNIKOVA SE et al.: Analysis of the structure, substrate specificity, and mechanism of squash glycerol-3-phosphate (1)-acyltransferase. Structure (Camb.) (2001) 9:347-353.
47. KENT C: Eukaryotic phospholipid biosynthesis. Annu. Rev. Biochem. (1995) 64:315-343.
48. KANFER J, KENNEDY EP: Metabolism and function of bacterial lipids: I. Metabolism of phospholipids in Escherichia coli B. J. Biol. Chem. (1963) 238:2919-2922.
49. KANFER J, KENNEDY EP: Metabolism and function of bacterial lipids: II. Biosynthesis of phospholipids in Escherichia coli. J. Biol. Chem. (2003) 239:1720-1726.
50. WAGGONER DW, GOMEZ-MUNOZ A, DEWALD J, BRINDLEY DN: Phosphatidate phosphohydrolase catalyzes the hydrolysis of ceramide 1-phosphate, lysophosphatidate, and sphingosine 1-phosphate. J. Biol. Chem. (1996) 271:16506-16509.
51. HSU SM, RAINE L, FANGER H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. (1981) 29:577-580.
52. BATTIFORA H, ALSABEH R, JENKINS KA, GOWN AM: Epitope retrieval (unmasking) in immunohistochemistry. Adv. Pathol. Lab. Med. (1995) 8:101-118.
53. HALBERT CL, DEMERS GW, GALLOWAY DA: The E7 gene of human papillomavirus Type 16 is sufficient for immortalization of human epithelial cells. J. Virol. (1991) 65:473-478.
54. BONHAM L, HOLLENBACK D, LEUNG D, WHITE T, MORRISON D, FINNEY RE: Validation of lysophosphatidic acid acyltransferase-β (LPAAT-β) as a novel target for anti-cancer drug discovery and development. Proc. Am. Assoc. Cancer Res. (New Orleans) (2001) 3608.
55. MILLER AD, ROSMAN GJ: Improved retroviral vectors for gene transfer and expression. Biotechniques (1989) 7:980-982, 984-986, 989-990.
56. SHEN Y, XU L, FOSTER DA: Role for phospholipase D in receptor-mediated endocytosis. Mol. Cell. Biol. (2001) 21:595-602.
57. JONES D, MORGAN C, COCKCROFT S: Phospholipase D and membrane traffic. Potential roles in regulated exocytosis, membrane delivery and vesicle budding. Biochim. Biophys. Acta (1999) 1439:229-244.
58. SERGEANT S, WAITE KA, HERAVI J, MCPHAIL LC: Phosphatidic acid regulates tyrosine phosphorylating activity in human neutrophils: enhancement of Fgr activity. J. Biol. Chem. (2001) 276:4737-4746.
59. PAWELCZYK T, MATECKI A: Phospholipase C-δ3 binds with high specificity to phosphatidylinositol 4,5-bisphosphate and phosphatidic acid in bilayer membranes. Eur. J. Biochem. (1999) 262:291-298.
60. BECHOUA S, DANIEL LW: Phospholipase D is required in the signaling pathway leading to p38 MAPK activation in neutrophil-like HL-60 cells, stimulated by N-formyl-methionyl-leucyl-phenylalanine. J. Biol. Chem. (2001) 276:31752-31759.
61. LEE SD, LEE BD, HAN JM et al.: Phospholipase D2 activity suppresses hydrogen peroxide-induced apoptosis in PC12 cells. J. Neurochem. (2000) 75:1053-1059.
62. BANNO Y, TAKUWA Y, AKAO Y et al.: Involvement of phospholipase D in sphingosine 1-phosphate-induced activation of phosphatidylinositol 3-kinase and Akt in Chinese hamster ovary cells overexpressing EDG3. J. Biol. Chem. (2001) 276:35622-35628.
63. SANJUAN MA, JONES DR, IZQUIERDO M, MERIDA I: Role of diacylglycerol kinase α in the attenuation of receptor signaling. J. Cell Biol. (2001) 153:207-220.
64. TOPHAM MK, PRESCOTT SM: Diacylglycerol kinase ζ regulates Ras activation by a novel mechanism. J. Cell Biol. (2001) 152:1135-1143.
65. JONES DR, SANJUAN MA, STONE JC, MERIDA I: Expression of a catalytically inactive form of diacylglycerol kinase α induces sustained signaling through RasGRP. FASEB J. (2002) 16:595-597.
66. ELBASHIR SM, HARBORTH J, LENDECKEL W et al.: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411:494-498.
67. WARTMANN M, DAVIS RJ: The native structure of the activated Raf protein kinase is a membrane-bound multi-subunit complex. J. Biol. Chem. (1994) 269:6695-6701.
68. CHAN TA, HERMEKING H, LENGAUER C, KINZLER KW, VOGELSTEIN B: 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature (1999) 401:616-620.
69. MOLZ L, BOOHER R, YOUNG P, BEACH D: cdc2 and the regulation of mitosis: six interacting mcs genes. Genetics (1989) 122:773-782.
70. FINNEY RE, BISHOP JM: Predisposition to neoplastic transformation caused by gene replacement of H-ras1. Science (1993) 260:1524-1527.
71. BONHAM L, HOLLENBACK D, MORRISON D, WHITE T: Lysophosphatidic acid acyltransferase-β: a novel target for anti cancer drug development. Keystone Symposium, Taos, NM, USA (2002):322.
72. JAIN M, ARVANITIS C, CHU K et al.: Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (2002) 297:102-104.
73. WEINSTEIN IB: Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis (2000) 21:857-864.
74. GORRE ME, MOHAMMED M, ELLWOOD K et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 293:876-880.
75. LA ROSEE P, JOHNSON K, O'DWYER ME, DRUKER BJ: In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp. Hematol. (2002) 30:729-737.